Enteric fever treatment
Reading File
Finding Sources
Finding Sources
Searching PubMed
"enteric fever" AND treatment
Reading File
Reading File
Reading File
Reading File
Reading File
I have the full antibiotic table from Harrison's and supporting information. Let me compile a comprehensive answer now.
Enteric Fever - Treatment
Enteric fever (typhoid and paratyphoid fever) caused by Salmonella Typhi and Paratyphi carries a case-fatality rate of 2.5% overall, rising to 10-30% if untreated. Prompt antibiotic therapy reduces mortality to <1%.
Antibiotic Therapy (Harrison's, 22e, 2025)
Empirical Treatment
| Agent | Dose | Route | Duration |
|---|---|---|---|
| Ceftriaxone | 2 g/day | IV | 10-14 days |
| Ciprofloxacin^b^ | 500 mg BID | PO | 5-7 days |
| Azithromycin^c^ | 1 g/day | PO | 10 days |
Fully Susceptible Strains
| Agent | Dose | Route | Duration |
|---|---|---|---|
| Ceftriaxone (optimal) | 2 g/day | IV | 10-14 days |
| Ciprofloxacin (optimal) | 500 mg BID | PO / 400 mg q12h IV | 5-7 days |
| Azithromycin (alt) | 1 g/day | PO | 5 days |
| Amoxicillin (alt) | 1 g TID | PO / 2 g q6h IV | 14 days |
| Chloramphenicol (alt) | 25 mg/kg TID | PO or IV | 14-21 days |
| TMP-SMX (alt) | 160/800 mg BID | PO | 7-14 days |
Multidrug-Resistant (MDR) Strains
For MDR strains (resistant to ampicillin, TMP-SMX, chloramphenicol):
| Agent | Dose | Route | Duration |
|---|---|---|---|
| Ceftriaxone (optimal) | 2 g/day | IV | 10-14 days |
| Ciprofloxacin (optimal) | 500 mg BID | PO | 5-7 days |
| Azithromycin (optimal) | 1 g/day | PO | 10 days |
| Cefixime (alt) | 200 mg BID | PO | 10-14 days |
Decreased Fluoroquinolone Susceptibility (XDR strains)
Extensively drug-resistant (XDR) S. Typhi - resistant to fluoroquinolones, ampicillin, TMP-SMX, chloramphenicol, and third-generation cephalosporins:
| Agent | Dose | Route | Duration |
|---|---|---|---|
| Azithromycin (optimal) | 1 g/day | PO | 10 days |
| Carbapenem (e.g., meropenem) | Weight-based | IV | 10-14 days |
Key Clinical Points
Fluoroquinolone resistance: Due to high prevalence of strains with decreased ciprofloxacin susceptibility (MIC >0.125 μg/mL) on the Indian subcontinent and parts of Africa, fluoroquinolones are no longer first-line empirical therapy for travelers from these regions. Azithromycin or ceftriaxone are preferred.
Uncomplicated enteric fever: Can be managed outpatient with oral azithromycin (1 g once, then 500 mg daily for 7 days). - Jawetz Medical Microbiology, 28e
Complicated/Severe enteric fever: Hospitalize and treat with parenteral third-generation cephalosporin or fluoroquinolone for at least 10 days. - Jawetz, 28e
Cefixime (oral): Effective but may increase risk of clinical failure and prolong time to defervescence compared with fluoroquinolones; used when IV therapy not possible. - Harrison's 22e
A 2022 systematic review of 27 RCTs found no significant difference between ceftriaxone, fluoroquinolones, and azithromycin in treatment failure, microbiologic failure, relapse, or adverse events. - Harrison's 22e
Severe Complications - Additional Management
- Intestinal perforation / GI bleeding: Immediate fluid resuscitation + surgical intervention + broadened antibiotics for polymicrobial peritonitis. Mortality from ileal perforation: 10-32%.
- Severe enteric fever with altered consciousness: Dexamethasone (3 mg/kg IV loading dose, then 1 mg/kg q6h for 48 hours) reduces mortality. This remains one of the few indications for glucocorticoids in acute bacterial infection. Steroids beyond 48 hours may increase relapse rate. - Harrison's 22e
Chronic Carrier State
- 2-5% of patients develop chronic carriage (>1 year excretion in stool/urine), especially with biliary abnormalities or gallstones.
- Treatment: Ampicillin or fluoroquinolone for 4-6 weeks. Most cases require cholecystectomy combined with antibiotics for definitive cure. - Jawetz, 28e
Prevention
- Ty21a vaccine (oral, live attenuated) - also offers limited protection against S. Paratyphi A and B.
- Vi polysaccharide vaccine (parenteral) - effective against S. Typhi only; does not protect against paratyphoid (no Vi antigen).
- A newer typhoid conjugate vaccine (TCV) is now WHO-recommended for children in endemic areas and provides longer-lasting immunity.
Sources: Harrison's Principles of Internal Medicine 22e (2025), p. 1361 | Jawetz Melnick & Adelberg's Medical Microbiology 28e | Fitzpatrick's Dermatology, Vol. 1-2
This is a shared conversation. Sign in to Orris to start your own chat.